Navigation Links
GPCR Screening and Profiling Market Trends 2013 in New Research Report at ReportsnReports.com
Date:8/30/2013

Dallas, Texas (PRWEB) August 30, 2013

This market report summarizes the results of industry-wide global web-based benchmarking survey on GPCR screening and profiling carried out in August 2013. The survey was initiated by HTStec as part of its tracking of life sciences marketplaces. The questionnaire was compiled to meet the needs, requirements and interests of the GPCR vendor community. The objectives were to comprehensively document current practices and preferences in GPCR primary screening and compound profiling, and to understand future user requirements, particularly with respect to the need for new assays, approaches and the use of outsourced services.

Purchase a report copy @ http://www.reportsnreports.com/Purchase.aspx?name=267694

The survey looked at both in house and outsourced GPCR primary screening and compound profiling, as practiced today (2013) and in some cases as predicted for the future (2015). Specifically the following were investigated: whether the number of GPCR primary screening targets or programs under investigation is changing; the proportion of GPCR screens that are cell-based and orphan receptors; use of different methods for assaying GPCR activation; preferred assay readout technology and supplier for GPCR screening; proportion of GPCR Ca2+ flux assays that are fluorescence-based; number of GPCR primary screens and wells per screen; approach to GPCR profiling; preferred assay readout technology and supplier for GPCR profiling; size of in house profiling panels and total wells profiled in house per year; how receptor panels are chosen; level of interest in outsourcing; methods of assaying GPCR activation that respondents wish to access by outsourcing; type of GPCR panels most interested to access at a fee-for-service provider; typical sizes of outsourced GPCR profiling panels used and total wells profiled per year at a fee-for-service providers; most trusted and most used providers of outsourced GPCR assay services; in house and outsourced budgets for GPCR screening and profiling; the breakdown of in house budgets; average costs paid per well for GPCR screening and profiling; level of interest in new assays/approaches for GPCR screening and profiling; suitability of available tools for new assays/approaches for GPCR screening and profiling; the proportion of GPCR assays that are made using primary cell lines and stem cell derived phenotypes; main barriers to the implementation of a new GPCR screening technology; where a GPCR reagent developer or assay fee-for-service provider should focus their efforts in the future; preferred way of sourcing GPCR expressing cell lines and the factors that drive decision making when sourcing; and any unmet needs in GPCR screening & profiling today.

The survey collected 96 validated responses, of these 66% provided comprehensive input. Survey responses were geographically split: 61% North America; 27% Europe; 7% Asia (excluding Japan); and 5% Japan.

Survey results were expressed as an average of all survey respondents. In addition, where appropriate the data was fully reanalyzed after sub-division into the following 5 survey groups: Pharma, Biotech, Academic Research, Europe and North America.

The median number of GPCR primary screening targets/programs under investigation in 2013 was 3.70% of GPCR primary screens were cell-based and 17% were orphan receptors in 2013.

The preferred GPCR readout technologies and suppliers for GPCR activation assays used in both primary screening and compound profiling were as follows: binding assays - radiometric from PerkinElmer; ß-arrestin recruitment or receptor internalization - chemiluminescence from DiscoveRx.

The preferred approach to GPCR profiling was to profile selected lead compounds only in the house. Median in house 2013 GPCR profiling metrics were: 2 to 3 new receptors added to the panel per year; a total of 6 to 10 receptors per panel; and 5K-10K wells profiled per year.

The types of GPCR panel respondents were most interested in accessing for outsourced compound profiling today (2013) were those that included all known GPCRs available. The median outsourced 2013 GPCR profiling metrics were: 6 to 10 receptors/profile and 1K-15K wells profiled per year.

Functional selectivity was rated the assay/approach for GPCR primary screening and compound profiling that respondents had more interest in using/evaluating. Receptor internalization and trafficking was the assay/approach for GPCR primary screening and compound profiling where the suitability of currently available tools was rated most effective.

Several bottom-up models were developed around the respondent's annual budgets to estimate the global markets for GPCR screening and profiling. At 2013 these markets were estimated to be as follows: in house GPCR primary screening reagents - $144M; in house GPCR compound profiling reagents - $28M; outsourced GPCR primary screening - $20M; and outsourced GPCR compound profiling - $24M. The market was segmented by organization and geography. CAGR estimates for 2015 were made for the market segments.

Complete report available @ http://www.reportsnreports.com/reports/267694-gpcr-screening-profiling-trends-2013.html

Browse more reports on Biotechnology Market @ http://www.reportsnreports.com/market-research/biotechnology/

About Us:

ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. We provide 24/7 online and offline support service to our customers.

Read the full story at http://www.prweb.com/releases/gpcr-screening-profiling/market-trends-analysis/prweb11077961.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
2. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
3. In Vitro Safety Screening for Clinical Liabilities, New Life Science Webinar hosted by Xtalks
4. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
5. BellBrook Labs and Tecan Offer Webinar on Screening Epigenetic Targets
6. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
7. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
8. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
9. BellBrook Labs and BMG Labtech to Offer Webinar on Integrated Platform for Screening Kinases and Methyltransferases
10. Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay
11. Isothermal Nucleic Acid Amplification Technologies Market 2012-2017: Molecular Diagnostics, Infectious Disease Testing, Blood Screening, Cancer Research, Rapid Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (NASDAQ: VWR), the leading global independent provider of product and ... financial results for the fourth quarter and full year ended ... 4Q16 record quarterly net sales of $1.13 billion, up 1.6% ... 4Q16 EMEA-APAC segment net sales increased 0.4%, ... sales increased 2.5%, or down 0.9% on an organic basis, ...
(Date:2/23/2017)... SAN RAFAEL, Calif., Feb. 23, 2017 ... of U.S. dollars, except per share data, unaudited)Three Months ... ChangeTotal BioMarin Revenue $ ...     22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... Calif. , Feb. 23, 2017  MIODx ... license for two key immunotherapy technologies from the ... technology provides a method to monitor a patient ... as PD-L1 and CTLA-4.  The second license extends ... a patient is likely to have an immune-related ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):